Skip to search formSkip to main content
You are currently offline. Some features of the site may not work correctly.

refametinib

An orally bioavailable selective MEK inhibitor with potential antineoplastic activity. Refametinib specifically inhibits mitogen-activated protein… Expand
National Institutes of Health

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2018
2018
Purpose: Refametinib, an oral MEK inhibitor, has demonstrated antitumor activity in combination with sorafenib in patients with… Expand
  • table 1
  • table 2
Is this relevant?
2017
2017
Purpose The MEK/MAPK pathway is commonly activated in HER2-positive breast cancer, but little investigation of targeting this… Expand
  • table 1
  • figure 1
  • figure 2
  • figure 3
  • figure 4
Is this relevant?
2016
2016
BackgroundActivating KRAS mutations are reported in up to 90% of pancreatic cancers. Refametinib potently inhibits MEK1/2, part… Expand
  • figure 1
  • table 1
  • figure 2
  • table 2
  • table 3
Is this relevant?
2016
2016
PURPOSE To assess the safety and tolerability of the small-molecule allosteric MEK inhibitor refametinib combined with sorafenib… Expand
  • figure 1
  • table 1
  • table 2
  • figure 2
  • table 3
Is this relevant?
2016
2016
Advanced or recurrent low-grade serous ovarian cancers (LGSC) are resistant to conventional systemic treatments. LGSC carry… Expand
  • table 1
  • table 2
  • figure 1
  • figure 2
  • figure 3
Is this relevant?
2015
2015
The multikinase inhibitor regorafenib (BAY 73-4506) exerts both anti-angiogenic and anti-tumorigenic activity in adult solid… Expand
  • figure 1
  • table 1
  • figure 2
  • table 2
  • table 2
Is this relevant?
2014
2014
PURPOSE There is an unmet need for treatment options in hepatocellular carcinoma (HCC). Sorafenib is currently the only approved… Expand
  • table 1
  • table 2
  • table 3
  • table 4
Is this relevant?
2014
2014
4129 Background: Refametinib is a potent oral allosteric MEK 1/2 inhibitor with both single-agent and synergistic activity in… Expand
Is this relevant?
2014
2014
2588 Background: Dual inhibition of the PI3K and MAPK signaling pathways is a promising strategy for optimal anticancer therapy… Expand
Is this relevant?
2013
2013
OBJECTIVE The objectives of the study were to evaluate the allosteric mitogen-activated protein kinase kinase (MEK) inhibitor BAY… Expand
Is this relevant?